Literature DB >> 3021281

Corticosterone reduces the excitability of hippocampal pyramidal cells in vitro.

C Vidal, W Jordan, W Zieglgänsberger.   

Abstract

In the rat brain, the hippocampus (HC) is a major target area for corticosterone (CT). In this study, we investigated the effects of CT in the in vitro slice preparation of the rat HC. Population spikes (PS) evoked by stratum radiatum stimulation were recorded in CA1. Bath-applied CT (10(-7)-10(-5) M) induced a decrease in the PS amplitude. This effect occurred within 10-15 min after the onset of CT perfusion, reached a plateau after 20-40 min and was reversible after 20 min washout. Neither dexamethasone (10(-5) M) nor vehicle produced any significant change in PS amplitude. Paired-pulse stimulation showed that the degree of inhibition of the second PS produced by the conditioning stimulus was either unchanged or decreased by CT. In the latter case, CT also reduced the inhibitory effect of gamma-aminobutyric acid on PS and enhanced the excitatory action of the opioid peptide D-Ala2-D-Leu5-enkephalin. These results show that CT reduces the excitability of HC pyramidal cells with a time course which may be compatible with a genomic action of CT. The fact that paired-pulse inhibition was either not changed or reduced, suggests that the decrease in PS size by CT is not due to an indirect excitatory effect of CT on inhibitory interneurons. Instead, CT may hyperpolarize pyramidal cells thus lowering their excitability and depressing the interneurons involved in recurrent inhibition.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021281     DOI: 10.1016/0006-8993(86)90007-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

1.  Hippocampal glucocorticoid receptor activation enhances voltage-dependent Ca2+ conductances: relevance to brain aging.

Authors:  D S Kerr; L W Campbell; O Thibault; P W Landfield
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

Review 2.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Corticosteroids: way upstream.

Authors:  Therese Riedemann; Alexandre V Patchev; Kwangwook Cho; Osborne F X Almeida
Journal:  Mol Brain       Date:  2010-01-11       Impact factor: 4.041

Review 4.  Functional implications of brain corticosteroid receptor diversity.

Authors:  E R de Kloet; M S Oitzl; M Joëls
Journal:  Cell Mol Neurobiol       Date:  1993-08       Impact factor: 5.046

5.  Mineralocorticoid receptor-mediated changes in membrane properties of rat CA1 pyramidal neurons in vitro.

Authors:  M Joëls; E R de Kloet
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Effect of corticosterone on noradrenergic nuclei in the pons-medulla and [3H]NA release from terminals in hippocampal slices.

Authors:  A S de Villiers; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

7.  Adrenalectomy increases local cerebral blood flow in the rat hippocampus.

Authors:  Y Endo; J Nishimura; F Kimura
Journal:  Pflugers Arch       Date:  1994-02       Impact factor: 3.657

8.  The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine.

Authors:  J Philbert; C Belzung; G Griebel
Journal:  Psychopharmacology (Berl)       Date:  2013-02-14       Impact factor: 4.530

9.  Alterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophrenia.

Authors:  Stephanie M Perez; Li Chen; Daniel J Lodge
Journal:  Psychoneuroendocrinology       Date:  2014-05-14       Impact factor: 4.905

10.  Dopamine-dependent responses to morphine depend on glucocorticoid receptors.

Authors:  M Marinelli; B Aouizerate; M Barrot; M Le Moal; P V Piazza
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.